SLAMF6 and neoplasm: In fact, B16 tumor cells are known targets for NK activity [40], despite some level of MHC-I expression, suggesting that the signals provided by ligation of the inhibitory receptors are overridden by signals from as yet unknown ligands for NK activating receptors, as B16 cells do not express ligands for the NKG2D receptor on NK cells [55].